Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. (3rd August 2019)

• Record Type: Journal Article
• Authors: Peyrin-Biroulet, Laurent; Danese, Silvio; Cummings, Fraser; Atreya, Raja; Greveson, Kay; Pieper, Burkhard; Kang, Taegyun
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 13:Number 8(2019)
• Page Start: 731
• Page End: 738
• Publication Date: 2019-08-03
• Subjects: Adalimumab -- biosimilars -- Crohn's disease -- infliximab -- tumor necrosis factor; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2019.1645595
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction : The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach. Areas covered : We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. Expert opinion : Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition cost-saving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future.